Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

4

Share

Download to read offline

East African Pharmaceutical Sector: Opportunities and Challenges

Download to read offline

Presentation by Nazeem Mohamed, Federation of East African Pharmaceutical Manufacturers made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.

Related Books

Free with a 30 day trial from Scribd

See all

East African Pharmaceutical Sector: Opportunities and Challenges

  1. 1. East African Pharmaceutical Sector: Opportunities and Challenges Nazeem Mohamed Director, Federation of East African Pharmaceutical Manufacturers (FEAPM) C.E.O Kampala Pharmaceutical Industries (1996) Ltd
  2. 2. Africa: The Healthcare Dilemma 11% of the World’s Population 24% of the World’s Disease Burden Less than 1% of the World’s Health Expenditure
  3. 3. Pharma Market Drivers
  4. 4. Therapy Area Attractiveness
  5. 5. EAC: Estimated Market Size US $ Millions Public Private Market size Uganda 220 102 322 Kenya 322 486 804 Tanzania 338 145 483 880 733 1,609 • Estimates based on available average monthly consumption data MoH and Pharma associations • UG and TZ public sector relatively higher due to substantial donor funding for Malaria and HIV/AIDS
  6. 6. EAC Pharma Manufacturing Summary • 35 active manufacturers but only 2 with WHO cGMP approval • Primarily Compounding and Formulation of most dosage forms including infusions • Production from imported API’s and other raw materials • Focus on WHO list of essential medicines • Well regulated (NDA, PPB, TFDA) • Trade is mostly intra-East Africa
  7. 7. EAC Political landscape: Supportive • Ongoing support to strengthen regulatory institutions and harmonize regulation (EAC-MRH) • Increasing political support for local pharmaceutical manufacturing • All Partner States have medicines policies, legislations and regulations in place
  8. 8. E.A. Pharmaceutical Market SWOT analysis Strengths •Population 130 M and growing middle class •Functioning policy and regulatory frameworks (in varying degrees across EAC partner states) •Relative economic and political stability •Higher returns than in the West Opportunities •Large unmet need and growth of chronic diseases (double disease burden) •New models of care being designed (e.g. PPP) •No dominant players!! •TRIPS flexibilities Weaknesses • High cost of operations e.g. finance, utilities, infrastructure •All API’s imported •Skill Gap •Unfair competition •Unable to access donor funds Threats •Lack of market data! •Negative perceptions of locally manufactured products •Cheap imports
  9. 9. Tips for Investing in East-Africa • Understand the market structure (informal and formal) • Take a longer term view – Operational challenges – Learning curve • Work with a local partner – Need to be close to the action – Invest in local talent • Understand the needs of the Government • Develop relationships!
  • ChetanPatil365

    Sep. 29, 2019
  • farissalama

    Oct. 7, 2018
  • AmitSonawane1

    May. 12, 2018
  • VinsentPaul

    Apr. 27, 2015

Presentation by Nazeem Mohamed, Federation of East African Pharmaceutical Manufacturers made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.

Views

Total views

5,477

On Slideshare

0

From embeds

0

Number of embeds

117

Actions

Downloads

371

Shares

0

Comments

0

Likes

4

×